Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Austar Lifesciences Ltd. ( (HK:6118) ) has provided an announcement.
Austar Lifesciences Limited has called its annual general meeting for 22 May 2026 in Shanghai, where shareholders will review and adopt the audited financial statements for the year ended 31 December 2025. The agenda also includes re-election of four directors, approval for the board to set director pay, re-appointment of Moore CPA Limited as auditor, and authorisation for the board to issue new shares up to 20 per cent of existing capital, with a potential additional 10 per cent tied to share repurchases.
These resolutions, if passed, will confirm the company’s 2025 financial reporting, refresh its board mandates, and secure continuity in external audit oversight. The proposed share issuance mandate would give the board wider flexibility in future fundraising and capital management, potentially supporting growth initiatives while diluting existing holdings within defined limits.
More about Austar Lifesciences Ltd.
Austar Lifesciences Limited is a Cayman Islands-incorporated company listed in Hong Kong, operating in the life sciences sector. The group serves pharmaceutical and related industries through specialised products and services, with its corporate governance and capital management overseen under Hong Kong listing regulations.
Average Trading Volume: 226,145
Technical Sentiment Signal: Sell
Current Market Cap: HK$425.4M
Learn more about 6118 stock on TipRanks’ Stock Analysis page.